Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.

HIV, HSV2, Primary prevention
dx.doi.org/10.1016/j.vaccine.2008.11.074, hdl.handle.net/1765/24519
Erasmus MC: University Medical Center Rotterdam

Freeman, E.E, White, R.G, Bakker, R, Orroth, K.K, Weiss, H.A, Buvé, A, … Glynn, J.R. (2009). Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine, 27(6), 940–946. doi:10.1016/j.vaccine.2008.11.074